Paul Burton, Moderna CMO
November 11, 2021 10:59 AM EST
Coronavirus

Covid-19 roundup: Mod­er­na notes high­er my­ocardi­tis risk for young males when com­pared to Pfiz­er's vac­cine; EMA signs off on Roche, Cell­tri­on mAb treat­ments

Zachary Brennan

Senior Editor

Mod­er­na’s new CMO Paul Bur­ton spoke to re­porters Thurs­day morn­ing, at­tempt­ing to de­fend his com­pa­ny’s vac­cine against ques­tions around heart-re­lat­ed risks that ap­pear to be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times